Vincent Wong

[Tom Marjot @tom_marjot]

1: In 2025, look out for a new section in @JHepatology:  "Breakthroughs Beyond the Journal". Editorial-style analyses of pivotal liver research

2: My comment on work from @Cell_Metabolism showing that MI drives #MASH. The interaction between these two diseases works BOTH ways 👇

[Jeffrey V. Lazarus @JVLazarus]

@EASLnews @AleksanderKrag @FrancqueSven @apdpdiabetes @brennap9 @MajaThiele @schattenbergJ @AlkhouriNaim @marurinella @FattyLiverA @fprusso73 @ajay_duseja @ArunJSanyalVCU @HannesHagstrom @rabataller @PoseElisa @LuisAntonioDiaz @BrettEFortuneMD @AlinaAllenMD @IsraelsenMads @tomhemmingk @NoureddinMD @melina_manolas @mromerogomez @DrJavierCrespo @FDA @JSGracia @juanpabloarab @Dr_Ampuero @pericas_jm @AASLDtweets @AmerGastroAssn @lucavalenti75 @SagiZelber @EuropeLiver @scottisaacsmd @ebtapper @EASOobesity @WorldObesity @JCabezasGlez @DrJLCalleja @LiverPatients @LiverAim @salvatore_piano Prof @SagiZelber presenting "Food inequity and insecurity and MASLD: burden, challenges, and interventions." We need to up our collaboration game and breakdown silos:
https://t.co/WjKjcuzpuD
@NatRevGastroHep #SLDsummit

[Vincent Wong @VWSWong]

@TerryYip12 @JHepatology @wonglaihung @CUHKMedicine @CUHKGI Congratulations, @TerryYip12 and friends!

[Terry Cheuk-Fung Yip @TerryYip12]

New study at @JHepatology unveils how two-step clinical care pathway for #MASLD predicts #MALOs. Many thanks to all collaborators! Explore our latest #VCTE-Prognosis Study: https://t.co/zGEAihtiij! @VWSWong @wonglaihung @CUHKMedicine @CUHKGI

[Vincent Wong @VWSWong]

What’s the best way to implement the 2-step clinical care pathway for evaluating MASLD? Is it as effective as VCTE for all patients? Check out this paper in J Hep: https://t.co/kE14CUXC1A. Congrats to @TerryYip12 and the VCTE-Prognosis Study Team! 🎉 #MASLD #ClinicalResearch

[Vincent Wong @VWSWong]

A new blood-based biomarker for #MASH has been confirmed in diverse US and Chinese populations. Amazing collaboration among @CUHKMedicine, @UCSDHealth, and Wenzhou Medical University! Read more in Cell Metabolism: https://t.co/lQFPeMM1D6

[Rohit Loomba @DrLoomba]

Call for abstracts for the MetALD Conference in San Diego Nov 14 at Westin Gaslamp Quarter- A star-studded panel of faculty from over 25 institutions worldwide - @VWSWong @MarcoArreseMD @QAnstee @DrHuangDQ @juanpabloarab @mcharltonmd
https://t.co/pazEqjAUBN
#livertwitter

[Vincent Wong @VWSWong]

This is probably the first MetALD Conference ever. Thank you, @DrLoomba, for hosting this in San Diego!
https://t.co/iSFIYTISws

[Gut Journal @Gut_BMJ]

Great new #GUTVideo by Su et al on

"Lactococcus lactis HkyuLL 10 suppresses colorectal tumourigenesis and restores gut microbiota through its generated alpha-mannosidase" via

https://t.co/423AIf0W4B

Paper via: https://t.co/Wrpq3uZ3ZN

@CUHKofficial @CUHKMedicine #ColorectalCancer

[Journal of Hepatology @JHepatology]

👋#LiverTwitter

What is your diagnosis❓

41yo woman: dark urine, scleral icterus, fatigue, shortness of breath, RUQ pain

➡️AST 364U/L
➡️ALT 393U/L
➡️ALP 155U/L
➡️Bilirubin 9.2 mg/dl

➡️Progestin-only OCP 7wks prior

History of photosensitivity

Case🔗https://t.co/nI19FXdflw

[Vincent Wong @VWSWong]

Achieving SVR doesn’t mean you’re free from liver cancer. The new AI-Safe-C score can identify patients at residual cancer risk. Stay informed! Congratulations, Huapeng! #Hepatology #LiverCancer #AI
https://t.co/vXm1nHQ7vY

[Journal of Hepatology @JHepatology]

🆕Article in press❕

Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome

Read it here👉https://t.co/HiIlndIDee

#LiverTwitter

[Jeffrey V. Lazarus @JVLazarus]

Excited to share our new review: "Food inequity and insecurity and MASLD: burden, challenges, and interventions"
https://t.co/WjKjcuzpuD, led by @SagiZelber, with @pericas_jm and more! @NatRevGastroHep
#LiverTwitter

[HEPATOLOGY Journal @HEP_Journal]

REVIEW
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Qi et al.
​​#LiverX @DrLoomba
https://t.co/YUWzpLHsxC

[Mattias Mandorfer @MattiasMandorf1]

Possibly the most satisfying achievement for physician-scientists: When your proposal stands the test of time & defines clinical practice.

👉 @BavenoCoop for cACLD after HCV-cure ➡️ @EASLnews Position Paper 🔗 https://t.co/X1oy3dCewp @JHepatology
🫶 @GeorgSemmler @SaSi_Lens

[roypounder.apt @APandT]

"Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: A single-centre prospective study" available open access at https://t.co/8GdUpnWYU5
#livertwitter

[Brett E Fortune MD @BrettEFortuneMD]

Important paper 🚨 👇🏻!!!

[roypounder.apt @APandT]

Published open access at https://t.co/AZgysVJeuC
"Faecal biomarkers for diagnosis and prediction of disease course in treatment-naïve patients with IBD"
#GIwitter

[Journal of Hepatology @JHepatology]

Van Gogh-like 2 is essential for the architectural patterning of the mammalian biliary tree

Full text here👉https://t.co/ZeREduK9Zc

#LiverTwitter

[roypounder.apt @APandT]

Patients with covert HE has a higher probability of developing overt HE than patients with other causes of neurocognitive impairment (NI). Read the full paper by Sultanik et al 'open access' at https://t.co/8PmEL1yVT5
#GItwitter